CTT Pharma Reduces Authorized Share Count
CTT Pharmaceuticals Holdings (OTC:CTTH) has announced a significant reduction in its authorized share count, cutting it by 150 million shares from 300 million to 150 million shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CTT Pharmaceuticals Holdings (OTC:CTTH) has announced a significant reduction in its authorized share count, cutting it by 150 million shares from 300 million to 150 million shares. The change has been officially filed with the Delaware Division of Corporations and recorded by the company's stock issuer.
The company states this adjustment reflects its commitment to optimizing its capital structure and creating long-term shareholder value. Additionally, CTT is pursuing approval for an uplisting to the OTCQB market.
Positive
- Reduction of authorized shares by 50% (from 300M to 150M shares)
- Pursuing uplisting to OTCQB from OTC markets
Negative
- None.
Details
News Market Reaction – CTTH
The recorded move for CTTH in the trading session of this news was +8.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / February 3, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC:CTTH) is pleased to announce a reduction in its authorized share count by 150 million shares. CTT reduced the authorized share count from 300 million shares to 150 million shares. This change has already been filed with Delaware Division of Corporations. Furthermore, CTT's stock issuer has been notified and made the necessary corrections to reflect this change. This latest adjustment demonstrates CTT Pharma's ongoing commitment to optimizing its capital structure and delivering long-term value to shareholders. CTT is also in the process of gaining approval to uplist to the OTCQB and believes this decision benefits existing and future shareholders.
About CTT Pharmaceuticals Holdings, Inc.
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceuticals Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.